Clinical trials: SARS CoV 2 Infection
COVID19
Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support
This is a randomized, double-blind, placebo-controlled, in which one dose of nangibotide will be tested versus placebo. All patients with a diagnosis of COVID-19, and a requirement for respiratory support will be considered for…
- Trial name
- ESSENTIAL (NCT04429334)
- Testing
- nangibotide
- Where
- 17 sites in Belgium, France
- Volunteers
- 220 people
- Sponsor
- Inotrem
Severe Acute Respiratory Syndrome Coronavirus 2
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers
This study is 'A Randomized Phase 1 Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy…
- Trial name
- NCT04461353
- Testing
- Aerolized Hydroxychloroquine Sulfate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pulmoquine Therapeutics, Inc
COVID-19, COVID-19 Pandemic
Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
The purpose of the study is to conduct a prospective evaluation of the diagnostic performance of the IVD CAPSULE COVID-19-NP test for antigenic determination of SARS-CoV-2 virus on the abioSCOPE® instrument.
- Trial name
- NCT05596032
- Where
- Italy
- Volunteers
- 440 people
- Sponsor
- Abionic SA
covid19
Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients
The aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compared to patients who receive…
- Trial name
- NCT04441398
- Testing
- Nitazoxanide
- Volunteers
- healthy volunteers welcome
- Sponsor
- Azidus Brasil
SARS-CoV-2 Infection, COVID-19
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
- Trial name
- NCT04368728
- Testing
- BNT162b1, BNT162b2, BNT162b2SA
- Where
- 175 sites in United States, Argentina and 4 more
- Volunteers
- 46,969 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
Evaluation of novel coronavirus induced severe pneumonia by dental pulp mesenchymal stem cells
- Trial name
- NCT04302519
- Testing
- Dental pulp mesenchymal stem cells
- Volunteers
- 24 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
Healthy Subjects
A Study to Explore the Physiological Impact of AIR+ KN95 Masks on Children
The primary objective is to evaluate the physiological impact of AIR+ KN95 Masks on end-tidal carbon dioxide (ETCO2) of children aged 7 to 14 years of age.
- Trial name
- NCT07037381
- Testing
- KN95 mask
- Where
- Singapore
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innosparks Pte Ltd.
Mild to Moderate COVID-19
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19
- Trial name
- COMBAAT (NCT04705844)
- Testing
- Adalimumab
- Sponsor
- Alachua Government Services, Inc.
COVID 19
Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients
More cases of COVID-19 pandemic are being reported daily around the world. It is highly infectious and, over 7 million people have been infected and more than 400,000 people have died globally till this date.
- Trial name
- HCQ-COVID19 (NCT04437693)
- Testing
- Hydroxychloroquine
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Patients With Moderate or Severe COVID-19
Efficacy of Amantadine Treatment in COVID-19 Patients
Demonstration of the efficacy of amantadine over placebo in the population of patients with moderate or severe COVID-19 in the initial stage of the disease treated in the hospital
- Trial name
- TITAN (NCT04952519)
- Testing
- Amantadine
- Where
- 12 sites in Poland
- Volunteers
- 193 people
- Sponsor
- Noblewell
SARS CoV 2 Infection
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients
This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 tablets in mild or moderate COVID-19 subjects.
- Trial name
- NCT05596045
- Testing
- ASC10
- Where
- 2 sites in United States
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
COVID-19
Breath Samples Collection Clinical Trial, for Development of the TERA BioStation T101, Intended for CoV-19 Exhalation Products Detection.
The Sponsor has developed a rapid screening tool intended to determine if the subject tested has COVID-19.
- Trial name
- NCT05162495
- Testing
- BioStation T101 and TeraTube
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tera Group
COVID-19
First-in-Human Study of Orally Administered GS-441524 for COVID-19
This is a two-part study is to evaluate the multi-day safety, tolerability, and pharmacokinetics (PK) of orally administered GS-441524 in a healthy human volunteer.
- Trial name
- NCT04859244
- Testing
- GS-441524
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Copycat Sciences LLC
SARS-CoV-2 Infection
A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
A randomised, blinded, parallel-controlled phase 1 clinical trial to evaluate the safety and preliminary immunogenicity of a COVID-19 mRNA vaccine in a healthy population aged 18 years and older, and to investigate immunisation…
- Trial name
- NCT06113744
- Testing
- COVID-19 Vaccine (Vero Cell) ,Inactivated, COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg, COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg
- Where
- China
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Covid19
Evaluating the Impact of EnteraGam In People With COVID-19
Background: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged as a potentially life-threatening disease in Wuhan, China, at the end of 2019.
- Trial name
- PICNIC (NCT04682041)
- Testing
- Bovine Plasma-Derived Immunoglobulin Concentrate, Standard of care
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Entera Health, Inc
Covid19, COVID-19 Lower Respiratory Infection
In-patient COVID-19 Study of Intranasal Foralumab
This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation.
- Conditions
- Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
- Trial name
- NCT04983446
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD
Coronavirus Infection, COVID-19
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19
The search for novel therapies to address the ongoing coronavirus (COVID-19) pandemic is ongoing. No proven therapies have been identified to prevent progression of the virus.
- Conditions
- Coronavirus Infection, COVID-19, Pneumonia, Viral
- Trial name
- NCT04358588
- Testing
- iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System
- Sponsor
- Bellerophon
COVID-19, Diabetes Mellitus
Incidence of Diabetes After a COVID-19 Infection
Prospective observational study of the POINTED consortium to evaluate whether new diagnoses of diabetes mellitus, occur significantly more frequently in the post-acute phase of a laboratory-confirmed SARS-CoV-2 infection than in…
- Trial name
- POINTED_Diab (NCT05524792)
- Testing
- no interventional study
- Where
- Germany
- Volunteers
- 157,134 people
- Sponsor
- InGef - Institute for Applied Health Research Berlin GmbH
SARS-CoV2 Infection, COVID-19
IMM-BCP-01 in Mild to Moderate COVID-19
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28.
- Trial name
- NCT05429021
- Testing
- IMM-BCP-01
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Immunome, Inc.
COVID-19
Phase I Double-blind, Placebo-controlled Study of AZD7442
AZD7442 mAbs are being evaluated for administration to prevent or treat COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD7442.
- Trial name
- NCT04896541
- Testing
- AZD7442 300 mg IM(male), AZD7442 600 mg IM (male), AZD7442 300 mg IV (male and female)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.